In a patient with a six‑month history of low back pain and morning stiffness lasting about one hour that improves with movement, and bilateral sacroiliitis on pelvic X‑ray, which test is most important to order?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HLA-B27 Testing is the Most Important Test

In this patient with confirmed bilateral sacroiliitis on X-ray and classic inflammatory back pain, HLA-B27 testing (Option D) is the most important laboratory test to order. This patient already has radiographic evidence of sacroiliitis, which substantially increases the pre-test probability of axial spondyloarthritis (axSpA), making HLA-B27 the highest-yield diagnostic test.

Why HLA-B27 is Superior in This Clinical Context

The clinical presentation—six months of inflammatory back pain with morning stiffness lasting one hour that improves with movement, combined with bilateral sacroiliitis on imaging—strongly suggests axSpA. HLA-B27 has a 90% sensitivity and 90% specificity for axSpA, with a likelihood ratio of 9 and post-test probability of 32% 1. This means only three patients with chronic back pain who are HLA-B27 positive need to be evaluated by a rheumatologist to diagnose one case of axSpA 1.

Critically, HLA-B27 positivity is also a predictor of worse prognosis 1, making it essential not just for diagnosis but for risk stratification and treatment planning. The test provides a clear binary result (positive/negative) with minimal variability and needs to be performed only once 1.

Why Other Tests Are Less Useful

Inflammatory Markers (ESR/CRP) - Option C

ESR and CRP have only 50% sensitivity in AS and early AS, with a post-test probability of merely 12% 1. This poor sensitivity means half of patients with axSpA will have normal inflammatory markers, making these tests unsuitable for screening or diagnosis 1. The guidelines explicitly state ESR/CRP are "not a suitable parameter for screening" 1.

Rheumatoid Factor - Option B

Rheumatoid factor is irrelevant in this context. The spondyloarthropathies are seronegative conditions by definition. RF testing would only be appropriate if considering rheumatoid arthritis as a differential diagnosis, which is not supported by this clinical presentation of axial symptoms with sacroiliitis.

Antinuclear Antibodies (ANA) - Option A

ANA testing has no role in diagnosing axSpA. While some patients with axSpA may have concurrent autoimmune conditions, ANA is not part of the diagnostic workup for spondyloarthritis and would not change management in this case.

Anti-CCP - Option E

Like rheumatoid factor, anti-CCP antibodies are specific for rheumatoid arthritis, not spondyloarthritis. This test would be inappropriate given the clinical presentation of inflammatory back pain with sacroiliitis rather than peripheral joint synovitis.

Clinical Algorithm for This Patient

  1. Order HLA-B27 testing immediately - This provides the highest diagnostic yield given the pre-existing radiographic sacroiliitis
  2. Refer to rheumatology - The combination of inflammatory back pain, bilateral sacroiliitis on X-ray, and (if positive) HLA-B27 essentially confirms the diagnosis 1
  3. Consider inflammatory markers as adjunctive information only - While ESR/CRP may be elevated, their absence does not exclude disease
  4. Document extra-articular manifestations - Ask specifically about uveitis, psoriasis, inflammatory bowel disease, and family history, as these strengthen the diagnosis 2, 3

Important Caveats

  • HLA-B27 negativity does not exclude axSpA - Approximately 10% of patients with axSpA are HLA-B27 negative 1. However, a positive result significantly strengthens the diagnosis and influences prognosis
  • The diagnosis is already highly likely - With bilateral sacroiliitis confirmed on imaging plus inflammatory back pain characteristics, this patient likely has axSpA regardless of laboratory results. The HLA-B27 test serves to confirm the diagnosis and assess prognosis rather than screen for disease
  • Cost-effectiveness is favorable - HLA-B27 testing costs approximately the same as a chest X-ray and only needs to be done once 1, making it cost-effective in this high-probability clinical scenario

The patient should be referred to rheumatology for definitive diagnosis and treatment initiation, as early intervention with appropriate therapy (NSAIDs, biologics if needed) can prevent progressive structural damage and preserve function 2, 4.

References

Related Questions

What are the typical symptoms and recommended treatment options for sacroiliitis?
What is the differential diagnosis, imaging interpretation, work‑up, and management for a 34‑year‑old woman with chronic unilateral left sacroiliitis on MRI (subchondral sclerosis and articular margin irregularity without marrow edema) presenting with left sacroiliac joint pain?
What is the recommended management for grade 2 sacroiliitis?
How can inflammatory sacroiliitis be distinguished from normal physiologic growth in pediatric patients using magnetic resonance imaging (MRI) and computed tomography (CT)?
What is the appropriate dose of indomethacin for a patient with severe sacroiliitis who is HLA‑B27 negative?
What is the recommended next step in management for a 30-year-old male with monthly periumbilical cramping pain, 1–2 episodes of vomiting, constipation/obstipation, increased bowel frequency to once every two weeks for 1.5 months, no weight loss or fever, after CT enterography and contrast‑enhanced CT abdomen and pelvis have been ordered?
What is the optimal next‑line systemic treatment for a patient with metastatic castration‑resistant prostate cancer adenocarcinoma with pleomorphic giant‑cell variant after recurrence following docetaxel therapy?
What is the recommended management of portal vein thrombosis in a patient with chronic liver disease?
What is the recommended management for subdural and intracerebral hematomas causing a midline shift?
When is calcium chloride indicated and what are the recommended dosing, administration route, and monitoring precautions for adults and children?
For a patient who is not a surgical candidate with elevated intracranial pressure, should I target a higher serum sodium level?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.